The Delaware District Court has ruled in favor of Acadia Pharmaceuticals Inc. in a patent infringement lawsuit concerning its Parkinson's disease drug, Nuplazid (pimavanserin). The court found that Aurobindo Pharma Ltd.'s proposed generic copies of Nuplazid capsules infringe on Acadia's formulation patent, which remains valid for more than 13 years. This decision upholds Acadia's exclusive rights to the drug's formulation. Additionally, the U.S. Patent and Trademark Office (USPTO) has accelerated its patent issuance timeline, impacting patent applicants and holders. Recent federal court rulings have also clarified aspects of intellectual property law, including petitioner estoppel and limits on inter partes review (IPR) estoppel. The case highlights ongoing developments in intellectual property rights enforcement and patent litigation within the pharmaceutical industry.